Health
Lassa fever: FG records 166 deaths, 895 confirmed cases in 21 states
By Wumi Tewogbade, Abuja
The Federal Government on Thursday, revealed that 166 deaths, 895 confined cases of Lassa fever in 9 month.
This was contained in a statement issued by Nigeria Centre for Disease Control and Prevention (NCDC) in Abuja.
It was revealed about 21 states were affected, while Ondo state have over 90% of confirmed cases comes from Ondo, Bauchi, Edo, Taraba, and Ebonyi State.
The statement reads, “The Nigeria Centre for Disease Control and Prevention (NCDC) has published the Lassa Fever Situation Report for Week 37 (8th– 14th September 2025).
“The number of confirmed cases decreased from 13 in Epi week 36 of 2025 to 11. The cases were reported in Ondo, Bauchi, Kogi and Anambra States.
“Cumulative for week 37 (2025) total: 895 confirmed cases, 166 deaths, CFR 18.5% (higher than 16.9% same period in 2024).
- 21 states have recorded at least one confirmed case across 106 LGAs.
“90% of confirmed cases are from Ondo, Bauchi, Edo, Taraba, and Ebonyi State.
“The predominant age group affected is 21- 30 years.
No new healthcare worker was affected this week. The number of suspected and confirmed cases decreased compared to that reported at the same period in 2024″.
Lassa fever symptoms usually begin with a gradual onset of fever, general weakness, and headache. After a few days, symptoms can progress to include muscle pain, chest pain, sore throat, nausea, vomiting, diarrhea, and cough. In severe cases, the illness can lead to bleeding, swelling, shock, and neurological issues, with long-term deafness possible in some survivors.
Health
Nigeria to Benefit from Anti HIV Injection Drug, Lenacapavir, Courtesy of USA
By Isa Abdul, Abuja
The first generic version of lenacapavir, a twice-yearly injection used to prevent HIV infection, has been given tentative approval by the U.S. Food and Drug Administration (FDA), in a major development for global HIV prevention.
The generic drug which has been developed by India’s Dr Reddy’s Laboratories, and is expected to cost about $40 per person annually, will be made available across 120 low- and middle-income countries, including Nigeria.
The injection has demonstrated near-total effectiveness in clinical trials, offering an alternative to daily HIV prevention pills. The approval is expected to accelerate access to affordable prevention options, although local regulatory processes, funding and distribution remain key to its rollout.
Health
NCDC Says Two Suspected Ebola Cases In Adamawa Test Negative
By Michael Lim
The Nigeria Centre for Disease Control (NCDC) has disclosed that the two suspected Ebola cases reported in Yola, Adamawa State, have tested negative following two rounds of laboratory testing.
The Agency noted in a statement that it is working with the Adamawa State Government to investigate the cases, which were isolated and tested.
The NCDC clarified that the index case previously confirmed in the Federal Capital Territory remains the only confirmed Ebola case reported in Nigeria.
It urged Nigerians to remain calm and rely on official government and public health channels for accurate information.
The Agency further advised anyone experiencing symptoms such as fever, severe weakness, headache, muscle pain, vomiting, diarrhoea or unexplained bleeding, particularly after possible exposure, to seek immediate medical attention and provide healthcare workers with relevant travel and contact history.
Health
NCDC: Two Suspected Ebola Cases in North-East Nigeria: Investigations, Lab Tests Ongoing
By Michael Lim
Two individuals have been isolated by health authorities following suspicion that they may be infected by Ebola disease in Nigeria’s North-East region as they are being subjected to investigations and lab tests.
An update on the disease situation by the Nigeria Centre for Disease Control and Prevention (NCDC), said contact identification and listing were ongoing, while samples from the suspected cases were being subjected to laboratory testing.
It clarified that the classification of the individuals as suspected cases did not mean they had tested positive for Ebola, noting that confirmation would depend on laboratory results.
The public was advised to maintain proper hand hygiene, practise enhanced sanitation and follow preventive guidance issued by public health authorities.
The update added that further information would be provided as verified details become available.
